BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense declines year over year

Q2 FY2026 income tax expense of $1.08M fell 23.0% year over year, behind the -0.9% change in trailing-twelve-month income tax expense. Sequentially, it rose 7.5% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.

Context

  • Income tax expense amounted to 0.4% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -23.0% toward the trailing-twelve-month pace of -0.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.08M+7.5% QoQ
Last fiscal yearDec 2025
$3.53M+83.2% YoY
LTMJun 2026
$3.49M-0.9% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.0%——
1 year+83.2%——
3-year CAGR+8.9%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
3.53M USD
Year-over-year change
+83.2%
4-year CAGR
+11.9%

Income Tax Expense vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -0.9% is the 3rd highest of 4, against a peer median of +67.6%.
  • Income tax expense amounts to 0.4% of revenue for BCRX, versus a peer median of 0.6%.
BCRX Competitors
Income Tax Expense for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$3.49M USD-0.9%+8.9%0.4%
PHVSPharvaris N.V.LTM Sep 2026€2.76M EUR+67.6%+43.1%—
VIRVir Biotechnology, Inc.LTM Mar 2026$371K USD+126.4%-90.3%0.6%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$6.32M USD-804.0%——
Peer median (excluding BCRX) —+67.6%-23.6%0.6%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.